Pancreatic Cancer
One of the World’s Most Critical Unmet Medical Needs
Cancer-Related Death
A Leading Cause of
467,000 deaths in 2022
+170% by 2045
Mortality is almost equal to incidence
Few patients survive long
after diagnosis
No Significant Therapeutic
Progress in Decades
Lowest survival rate of all major cancers
1-year survival of only ~23-25%
5-year survival of only ~7-9%
Standard chemotherapies offer
limited benefit and high toxicity
Diagnosed Too Late,
Protected Too Well
Most patients are diagnosed at advanced or metastatic stages
Pancreatic tumors are characterized by a dense and protective stromal barrier
The stroma prevents drugs and
immune cells from reaching the tumor
About
SPLITE
Our technology, SPLITE, is a dual-action photoactivated chemotherapy engineered to overcome the key resistance mechanisms of pancreatic cancer. It simultaneously remodels the dense tumor stroma and delivers a potent anticancer effect. By enhancing the efficacy of standard-of-care therapies, SPLITE offers a transformative treatment approach where conventional therapies alone show limited benefit.
Validated Preclinical
Proof of Concept
SPLITE is de-risked with compelling preclinical evidence, demonstrating robust anticancer efficacy and excellent biotolerability across diverse in vivo studies, including orthotopic and patient-derived xenograft (PDX) models — supporting TRL4 validation. LITE Therapeutics is now strengthening its preclinical data package to secure an EMA-approved First-in-Human clinical trial and accelerate SPLITE’s path to patients.
Chemistry Ready
for Scale-Up
Demonstrated Tumor Regression
11x Superior Efficacy vs. SoC
Excellent Biotolerability
with No Observed Toxicity